Iovance raises FY2026 revenue guidance to $410M-$420M from $350M-$370M

Iovance Biotherapeutics raised its full-year 2026 total revenue guidance to $410M-$420M from a prior range of $350M-$370M.

Detected & updated continuously · Source: Nebula